HEALTH

Thync launches neurosignaling device to either energize or induce calm

BY Michael Johnsen

LOS GATOS, Calif. — Thync has launched a consumer wearable designed to either energize the user or make them calmer. The neurosignaling device is operated with an accompanying app to deliver Thync Vibes, the company stated.
 
"Our mission at Thync is to ‘unlimit’ people. Thync brings together innovations in neuroscience and engineering so you can access your own abilities," said Isy Goldwasser, CEO Thync.  “Our product will help many people improve and enjoy their life more.”
 
Based upon research from neuroscientists and engineers from Harvard, MIT, Stanford and Arizona State University, Thync's proprietary technology relies on low levels of pulsed electrical energy to signal specific neural pathways, allowing users to dial up or dial down their stress responses and energy levels.
 
“Today's fast-paced life requires us to switch situations and change mindsets at increasing speed. Thync helps people find calm and focus throughout your day,” said Jamie Tyler, chief science officer. “Thync is the result of groundbreaking research at some of the best academic institutions, combined with cutting-edge engineering that leverages patented algorithms. This has culminated in today's launch of a device that, for the first time, lets you safely tap into the power of your own mind.”
 
Based on its intended use in lifestyle applications, the Food and Drug Administration exempted the Thync System from medical device regulations requiring pre-market notification or approval, Thync stated. 
 
Thync can be purchased at www.Thync.com for $299.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

GoJo makes commitment to antibiotic stewardship

BY Michael Johnsen

AKRON, Ohio — GoJo pledged its commitment to antibiotic stewardship at the White House Forum on Tuesday.  GoJo was among 150 companies at the White House Forum to announce commitments over the next five years to slow the emergence of antibiotic-resistant bacteria, detect resistant strains, preserve the efficacy of existing antibiotics and prevent the spread of resistant infections.
 
“A primary prevention approach to reduce the need for antibiotics is effective hand hygiene,” Joe Kanfer, chairman and CEO of GoJo, who is attending the Forum, said. “As we know, hand hygiene is one of the best measures you can take to prevent the spread of illness-causing germs. Staying healthy and preventing infections from happening is a very effective way to reduce the use of antibiotics. This is why practicing good hand hygiene — handwashing and hand sanitizing — is so important to overcoming the challenge of antibiotic resistance. We look forward to working with other organizations that share this dedication to improving public health.”
 
Last year, President Barack Obama signed an Executive Order launching Federal efforts to combat the rise in antibiotic-resistant bacteria. The Administration also issued its National Strategy on Combating Antibiotic-Resistant Bacteria, which outlines steps the U.S. government will take to improve prevention, detection and control of resistant pathogens. Earlier this year, the White House released its National Action Plan to Combat Antibiotic-Resistant Bacteria, an effort that identifies critical actions to be taken by government over the next five years. In addition, the President's FY 2016 Budget proposed nearly doubling the amount of Federal funding for combating and preventing antibiotic resistance to more than $1.2 billion.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Perrigo buys international OTC portfolio from GSK

BY Michael Johnsen

DUBLIN — Perrigo on Tuesday acquired a portfolio of OTC brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK's commitments to the European Commission and other regulators to divest these businesses because of its consumer health joint venture with Novartis. 
 
Terms of the all-cash transaction were not disclosed.
 
Included in the deal are GSK's NiQuitin nicotine replacement therapy business, primarily in the European Economic Area and Brazil, and Novartis's legacy Australian NRT business, including the Nicotinell brand; several assorted OTC brands including Coldrex (cold and flu treatment) across the EEA, and Panodil (pain relief), Nezeril (nasal decongestant) and Nasin (nasal decongestant) in Sweden; and Novartis' legacy cold sore management products primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.
 
"This acquisition demonstrates Perrigo's ability to execute on our 'Base Plus Plus Plus' strategy, in which we make selective, accretive transactions to expand our durable base business," stated Joseph Papa, Perrigo president and CEO. "We are building on the global platform we established with the Omega Pharma acquisition to capture an even greater share of the $30 billion European OTC market opportunity with several well-established, complementary brands that bolster our OTC product portfolio. We are committed to making investments in these brands to grow their market positions in key geographies, by following Omega Pharma's proven approach to brand building."
 
"Perrigo is uniquely positioned to maximize the potential of these brands by leveraging Omega Pharma's leading European commercial infrastructure, pan-European distribution network, strong brand-building capabilities and exceptional management team. This announcement comes on the heels of our recent acquisition of European OTC dermatological product, Vitasil, which recently closed. With our global platform in place and our robust balance sheet, we are ideally positioned to execute immediately accretive deals, such as this one, that will have a multiplier effect on our growth."  
 
The transaction has been unanimously approved by the boards of directors of Perrigo and GSK, and is expected to close in the third quarter of 2015, pending approval by the European Commission, the Australian Competition and Consumer Commission, and Brazil's Council for Economic Defense, as well as the satisfaction of customary closing conditions.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?